Hexarelin Dosage Guide

Dosage overview

Dosing notes

Inject subcutaneously, typically into the abdomen, at least 2 hours after a meal. Wait 20 to 30 minutes before eating to avoid insulin-driven blunting of the GH response. Because hexarelin desensitizes faster than other GHRPs, most research protocols limit injection frequency to 1 to 2 times daily rather than the 3 times daily used with GHRP-2 or ipamorelin. The most effective timing windows are morning (fasted upon waking) and pre-sleep (2 hours after the last meal), capturing the natural GH pulse that accompanies slow-wave sleep onset. Stacking with a GHRH analog such as CJC-1295 or modified GRF(1-29) amplifies the GH response substantially and is standard practice when maximum GH output is the goal. The short recommended cycle length is a hard constraint rooted in receptor biology, not a conservative estimate. Users who try to extend hexarelin cycles beyond 8 weeks consistently report declining effectiveness that does not improve with dose increases. A 4-week minimum break between cycles is necessary to allow GHS-R1a receptor resensitization before the next cycle begins.

Important safety information

Dosage ranges listed above are based on available research data and reported protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.

• Start at the lowest effective dose and titrate up gradually
• Monitor for side effects, especially during dose increases
• Do not exceed researched dose ranges without medical supervision
• This is a research compound — human dosing guidelines are not FDA-established

Research references

• Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during somatostatin infusion and after exogenous somatostatin and GHRH in humans — Journal of Clinical Endocrinology and Metabolism (1994) [PubMed]
• Comparison of growth hormone (GH)-releasing peptides: stimulation of GH release from perifused rat anterior pituitaries by GHRP-1, GHRP-2, GHRP-6, hexarelin, and MK-0677 — Endocrinology (1997) [PubMed]
• Hexarelin peptide: a growth hormone-releasing peptide with cardioprotective activity — Proceedings of the National Academy of Sciences (2000) [PubMed]